A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Trial Details

NCT ID
NCT06478693
Phase
PHASE1
Sponsor
Myeloid Therapeutics
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • MT-303
  • MT-303 +Atezolizumab + Bevacizumab
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Woolloongabba, Queensland, Australia|-27.48855,153.03655
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Murdoch, Western Australia, Australia|-32.06987,115.83757
  • Busan, South Korea|35.10168,129.03004

Key Eligibility Criteria

  • Aged 18 years or older
  • Histological diagnosis of advanced/recurrent or metastatic and/or unresectable HCC. \[Note: participants with other tumor types expressing GPC3 may…
  • Measurable lesion per RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →